Format

Send to

Choose Destination
Curr Opin Immunol. 2017 Dec;49:37-43. doi: 10.1016/j.coi.2017.08.013. Epub 2017 Sep 18.

Immunomodulation in multiple sclerosis: promises and pitfalls.

Author information

1
Nuffield Department of Medicine, The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
2
Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology and MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK. Electronic address: lars.fugger@imm.ox.ac.uk.

Abstract

Multiple sclerosis (MS) afflicts about 2.5 million people globally and poses a major personal and socioeconomic burden. The recognition of MS as an inflammatory disease, characterized by infiltration of immune cells into the central nervous system, has spurred research into the autoimmune etiology of the condition and has provided the rationale for its treatment through immunomodulation. Experience with immunotherapies in MS to date has suggested a disparity between the observed immune cell infiltration and the progressive loss of neurons. However, recent clinical efforts are providing new insights into progressive MS that once again place the immune system at center stage. This article reviews the main mechanisms of MS immunopathogenesis, and the benefits, risks and challenges of immunomodulatory treatments for the disease.

PMID:
28926740
DOI:
10.1016/j.coi.2017.08.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center